Cargando…
Targeting Oncogenic Mutant p53 for Cancer Therapy
Among genetic alterations in human cancers, mutations in the tumor suppressor p53 gene are the most common, occurring in over 50% of human cancers. The majority of p53 mutations are missense mutations and result in the accumulation of dysfunctional p53 protein in tumors. These mutants frequently hav...
Autores principales: | Parrales, Alejandro, Iwakuma, Tomoo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685147/ https://www.ncbi.nlm.nih.gov/pubmed/26732534 http://dx.doi.org/10.3389/fonc.2015.00288 |
Ejemplares similares
-
p53 as a Regulator of Lipid Metabolism in Cancer
por: Parrales, Alejandro, et al.
Publicado: (2016) -
Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018) -
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
por: Iyer, Swathi V., et al.
Publicado: (2015) -
DNAJA1- and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen
por: Nishikawa, Shigeto, et al.
Publicado: (2022) -
Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin
por: Alalem, Mohamed, et al.
Publicado: (2022)